Company news

Natera, Inc. news in 2024

Natera, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Court Grants Natera’s Request to Include Additional Patent in its Lawsuit Against NeoGenomics

December 16, 2024

Natera Announces Enrollment of First Patients in SAGITTARIUS: a Randomized, Phase III Clinical Trial in Colon Cancer

December 11, 2024

Natera and MyOme Announce Launch of iPRS™ for Breast Cancer Risk Assessment

December 8, 2024

Clinical Validation Study on Natera’s Fetal RhD NIPT Published in Obstetrics & Gynecology

December 1, 2024

Natera Announces Medicare Coverage for Prospera™ in Single Lung Transplant Recipients

November 26, 2024

Natera to Present New SignateraTM Data in Multiple Abstracts at the San Antonio Breast Cancer Symposium

November 24, 2024

Natera Issues Statement on Guardant Health Litigation

November 24, 2024

Natera Co-Founder and Executive Chairman Matthew Rabinowitz Named 2024 R&D Leader of the Year

November 24, 2024

Natera Announces Publication of over 100 Peer-Reviewed Papers on SignateraTM

November 20, 2024

Natera Reports Third Quarter 2024 Financial Results

November 11, 2024

Natera Announces Completion of Signatera™ Analysis from the CALGB (Alliance)/SWOG 80702 Randomized, Phase III Clinical Trial in Colorectal Cancer

November 11, 2024

Natera to Participate in Upcoming Investor Conferences

November 7, 2024

Natera to Report its Third Quarter 2024 Results on November 12, 2024

October 31, 2024

Natera to Present New Renasight Data at ASN Kidney Week 2024

October 21, 2024

Court Orders Permanent Injunction Against NeoGenomics' Accused RaDaR Assay, as Case Enters New Phase

September 22, 2024

Natera Announces Three New Signatera Publications; Includes Groundbreaking Overall Survival Data Published in Nature Medicine and also Released at ESMO

September 15, 2024

First of its Kind Colorectal Cancer Data from Prospective GALAXY Study Released at ESMO; Demonstrates Signatera's Ability to Predict Overall Survival

September 13, 2024

Natera to Present New Signatera™ Colorectal Cancer Data at ESMO Showing 10X Advantage in Overall Survival

September 7, 2024

Natera to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

August 27, 2024

Natera Reports Second Quarter 2024 Financial Results

August 7, 2024

Natera to Participate in the Canaccord Genuity 44th Annual Growth Conference

August 5, 2024

Natera to Report its Second Quarter 2024 Results on August 8, 2024

July 29, 2024

New MultiCenter Prospective Study Demonstrates Signatera’s Clinical Utility in Merkel Cell Carcinoma

July 25, 2024

Natera to Present at the 28th International Conference on Prenatal Diagnosis and Therapy

July 2, 2024

Natera Announces DECIPHER: A Phase II, Single-Arm Adjuvant Trial in Gastroesophageal Cancer

June 26, 2024

Natera Launches Differentiated New Feature for Prospera™ Heart Test, Enhancing Detection of Rejection for Transplant Patients

June 16, 2024

Natera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

June 2, 2024

Natera Presents Latest in Transplant Innovation Data Across Multiple Organs at ATC 2024

May 29, 2024

Natera to Present at the 2024 Leerink Partners Healthcare Crossroads Conference

May 22, 2024

Natera Announces New MRD Data in Multiple Tumor Types, to be Presented at ASCO Annual Meeting

May 22, 2024

Natera Reports First Quarter 2024 Financial Results

May 8, 2024

New Natera Publication Bolsters Evidence for Extended Surveillance with Signatera™ in Breast Cancer

May 2, 2024

Natera to Report its First Quarter 2024 Results on May 9

April 30, 2024

Natera Launches Fetal RhD NIPT Supporting Ob/Gyn Physicians and Patients During RhIg Shortage

April 30, 2024

Natera Announces Significant Milestone with 200+ Peer-Reviewed Publications

April 21, 2024

Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation

April 10, 2024

Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant Recipients

April 7, 2024

Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer

April 4, 2024

Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer

March 31, 2024

Natera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™ in Stage II Colorectal Cancer

March 17, 2024

New KDIGO Guideline Supports Genetic Testing for the Majority of CKD Patients to Establish Cause of Disease

March 13, 2024

Natera to Present New Data at the 2024 SGO Annual Meeting on Women’s Cancer, Following Recent Medicare Coverage Decisions in Ovarian and Breast Cancers

March 11, 2024

Natera Announces Commercial Coverage for Prospera™ Kidney and Prospera Heart™ from a Top BCBS Plan

March 6, 2024

Natera to Participate in March Investor Conferences

February 28, 2024

Natera Reports Fourth Quarter and Full Year 2023 Financial Results

February 27, 2024

Natera Announces Next Phase of CareDx Patent Infringement Litigation Seeking Royalty For All Ongoing And Future AlloSure Tests

February 26, 2024

Medicare Extends Coverage of Natera’s Signatera™ MRD Test to Ovarian Cancer and Neoadjuvant Breast Cancer

February 25, 2024

Natera Announces Fourth Quarter and Fiscal 2023 Earnings Conference Call

February 19, 2024

New Study Validates Signatera™ in Endometrial Cancer

February 4, 2024

New Publication Demonstrates Signatera’s Ability to Risk Stratify and Detect Recurrence Early in Resected Stage I-II Lung Cancer

January 29, 2024

Older news releases →

Calls in 2024

Decks in 2024